Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required)
ID: 357602Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357602

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-279.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering Exploratory Clinical Trial Grants (R61) to support research in arthritis and musculoskeletal and skin diseases. This funding opportunity aims to facilitate short-term, interventional studies that address critical research questions, particularly those evaluating drug efficacy in rare diseases, without requiring preliminary data. Grants can provide up to $600,000 over three years, with applications due by November 2, 2026. Interested applicants are encouraged to consult with NIH staff during the application process and can find additional information at NIH Grants or by contacting NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-279-Full-Announcement.html
    PAR-24-279.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), announces an opportunity for Exploratory Clinical Trial Grants (R61) aimed at advancing research in arthritis and musculoskeletal skin diseases. The funding seeks to support short-term, interventional studies that address critical research questions aligned with the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Grant applications must propose clinical trials, adhering to specific eligibility criteria. The overall project funding can reach up to $600,000 over three years, with an application deadline of July 2, 2026. Notable considerations include early-stage clinical trials aimed at evaluating drug efficacy, particularly in rare diseases, without the necessity of preliminary data. Applicants are encouraged to engage with NIAMS staff for consultation during application development, discussing timelines and recruitment strategies. The selection will be based on scientific merit, potential impact, and the feasibility of the proposed approach, with strict adherence to guidelines required for submission through designated electronic platforms. This initiative emphasizes innovation and the translation of promising research into clinical practice, reflecting NIH's commitment to advancing the health outcomes of affected populations.
    Similar Opportunities
    Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering funding opportunities through the "Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases" program, specifically under the R61 Clinical Trial mechanism. This initiative aims to support short-term exploratory clinical trials that investigate treatments for rheumatic, musculoskeletal, and skin conditions, with a focus on diverse therapeutic approaches. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and state and local governments, with a maximum budget of $600,000 for a three-year project, not exceeding $300,000 in any single year. Applications must be submitted electronically via Grants.gov, with key deadlines starting from February 4, 2024, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov. For more details, visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-035.html.
    Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Clinical Observational (CO) Studies focused on musculoskeletal, rheumatic, and skin diseases, under the grant title PAR-24-036. This grant, which does not allow clinical trials, aims to support observational studies that collect critical data to inform future clinical research, particularly regarding disease symptoms, progression, and participant eligibility, while also exploring telehealth and digital outcomes. The initiative is designed to enhance the rigor of future clinical trials through comprehensive data collection from diverse populations, ultimately improving patient outcomes in affected communities. The grant provides up to $475,000 over four years, with applications opening on February 4, 2024, and funding decisions expected by late 2024. Interested applicants can find more information and guidelines at NIH Grants or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases under the R01 Research Project Grant program. This initiative aims to support observational studies that gather critical data to inform future clinical research, focusing on understanding disease symptoms, progression, participant recruitment strategies, and potential biomarkers. The funding opportunity is significant for enhancing research outcomes in health fields related to these diseases, with applicants eligible to request up to $475,000 over four years. Key deadlines include an application submission start date of February 4, 2025, and a final expiration date of November 3, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3), aimed at supporting interventional clinical trials focused on rheumatic, musculoskeletal, and skin diseases. This initiative encompasses a two-phase approach, where the UG3 phase involves trial preparation and the UH3 phase focuses on trial execution, contingent upon meeting specific milestones. The program emphasizes the importance of developing clinical protocols, obtaining IRB approval, and securing necessary resources, while also promoting health equity by engaging individuals with lived experience in the research process. Interested applicants can apply for funding up to $250,000 for the UG3 phase, with a closing date for submissions set for March 4, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-208.html.
    NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), is offering a funding opportunity for the implementation of interventional clinical trials via the Clinical Trial Implementation Cooperative Agreement (UG3/UH3). This initiative aims to support investigation-driven projects for both single and multi-site trials across all phases, emphasizing the importance of preliminary planning and the completion of necessary approvals before trial execution. The funding opportunity reflects NIAMS' commitment to advancing research in arthritis and musculoskeletal diseases, with grants of up to $250,000 available for the UG3 phase and no specific limit for UH3 project budgets, designed for up to six years of support. Interested applicants can find more information and application details at the provided link, with the application deadline set for March 4, 2027.
    Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing an upcoming funding opportunity titled "Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)," aimed at supporting research that leverages resources from ongoing clinical studies. This initiative encourages applications for ancillary studies that utilize well-characterized patient cohorts, infrastructure, data, and biological samples, while aligning with the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). With an estimated total program funding of $600,000 and the expectation of awarding two grants, potential applicants are advised to begin developing collaborations and project proposals in advance of the official solicitation, which is expected to be published in early 2026. For further inquiries, interested parties may contact Dr. Heiyoung Park at Heiyoung.Park@nih.gov or by phone at 301-594-5032.
    Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)" aimed at supporting research that leverages resources from ongoing clinical studies. This initiative encourages applications for ancillary studies that align with the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), utilizing well-characterized patient cohorts, infrastructure, data, and biological samples from parent studies. With an estimated total program funding of $2 million and an expected four awards, interested small businesses are encouraged to collaborate and develop responsive projects. Key deadlines include an estimated synopsis post date of February 4, 2026, a close date of April 6, 2026, and an anticipated award date of December 4, 2026. For further inquiries, applicants can contact Heiyoung Park, Ph.D., at Heiyoung.Park@nih.gov or by phone at 301-827-5992.
    Resource-based Centers for Rheumatic Diseases Research
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to announce a funding opportunity for Resource-based Centers for Rheumatic Diseases Research, aimed at enhancing research infrastructure for rheumatic diseases. This initiative will support small businesses in providing shared facilities, services, and resources to facilitate collaborative research efforts among investigators in this field. The goal is to accelerate and enrich ongoing basic, translational, and clinical research aligned with the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). While applications are not currently being solicited, interested parties are encouraged to develop collaborations and project proposals in anticipation of the upcoming Notice of Funding Opportunity (NOFO), with an estimated synopsis posting date of September 3, 2025, and a closing date of November 3, 2025. For further inquiries, potential applicants can contact Dr. Mary Garcia-Cazarin at mary.garcia-cazarin@nih.gov or by phone at 301-451-2937.
    Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed)" aimed at supporting clinical projects that enhance readiness for clinical trials in rare diseases. This initiative seeks applications that focus on developing and testing biomarkers and clinical outcome measures, as well as defining the characteristics of rare diseases to facilitate the design of future clinical trials. The program is particularly important for addressing the needs of rare diseases affecting fewer than 200,000 individuals in the U.S., with a maximum budget of $275,000 for direct costs over a project period of up to two years. Interested applicants can find more information and submit inquiries via email to grantsinfo@nih.gov, with the application deadline set for July 20, 2028.
    Core Centers for Clinical Research (CCCR) (P30 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Core Centers for Clinical Research (CCCR)" aimed at advancing methodological sciences in clinical research related to musculoskeletal, rheumatic, and skin diseases. This initiative seeks to establish centers that will focus on the prevention, diagnosis, and treatment of these conditions, emphasizing the development of novel methods and metrics while ensuring community representation throughout the research process. Eligible applicants include small businesses, with no cost-sharing or matching requirements, and the estimated project start date is set for July 1, 2027. Interested parties can reach out to Dr. Melissa C. Green Parker at melissa.greenparker@nih.gov or by phone at 240-755-3031 for further information, with the application period expected to close on September 25, 2026.